Humana Inc. v. Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and Glenmark Pharmaceuticals Ltd.; Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp. v. AmerisourceBergen Drug Corp., AmerisourceBergen Corp., and Cencora, Inc.

CourtDistrict Court, D. New Jersey
DecidedJanuary 14, 2026
Docket2:23-cv-23023
StatusUnknown

This text of Humana Inc. v. Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and Glenmark Pharmaceuticals Ltd.; Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp. v. AmerisourceBergen Drug Corp., AmerisourceBergen Corp., and Cencora, Inc. (Humana Inc. v. Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and Glenmark Pharmaceuticals Ltd.; Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp. v. AmerisourceBergen Drug Corp., AmerisourceBergen Corp., and Cencora, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Humana Inc. v. Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and Glenmark Pharmaceuticals Ltd.; Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp. v. AmerisourceBergen Drug Corp., AmerisourceBergen Corp., and Cencora, Inc., (D.N.J. 2026).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

HUMANA INC.,

Plaintiff, Case No. 2:23-cv-23023 (BRM) (LDW)

v. OPINION

MERCK & CO., INC., MERCK SHARP & DOHME CORP., SCHERING-PLOUGH CORP., SCHERING CORP., and GLENMARK PHARMACEUTICALS LTD.,

Defendants.

MERCK & CO., INC., MERCK SHARP & DOHME CORP., SCHERING-PLOUGH CORP., and SCHERING CORP.,

Third-Party Plaintiffs,

v.

AMERISOURCEBERGEN DRUG CORP., AMERISOURCEBERGEN CORP., and CENCORA, INC.,

Third-Party Defendants.

MARTINOTTI, DISTRICT JUDGE Before this Court is Third-Party Defendants AmerisourceBergen Drug Corporation, AmerisourceBergen Corporation, and Cencora, Inc. f/k/a AmerisourceBergen Corporation’s (collectively, “Cencora”) Motion to Dismiss Defendants/Third-Party Plaintiffs Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp.’s (collectively, “Merck”) Third-Party Complaint (ECF No. 68) pursuant to Federal Rule of Civil Procedure (“Rule”) 12(b)(6) or, alternatively, to Transfer Venue to the Eastern District of Virginia pursuant to 28 U.S.C. § 1404(a) (the “Motion”) (ECF Nos. 83, 84, 85). Merck filed an Opposition (ECF Nos. 86, 87), and Cencora filed a Reply (ECF Nos. 95, 96). Both parties subsequently filed Notices of Supplemental Authority1 (ECF Nos. 116, 117, 144), and Cencora filed a response to Merck’s

Notice of Supplemental Authority (ECF No. 118). This Court has jurisdiction pursuant to 42 U.S.C. § 1332(a). Having reviewed and considered the parties’ submissions filed in connection with the Motion and having declined to hold oral argument in accordance with Rule 78(b), for the reasons set forth below and for good cause shown, Cencora’s Motion to Dismiss is DENIED, Cencora’s Motion to Transfer Venue is DENIED, and the third-party action is stayed for ninety days to allow the parties to complete mediation efforts before the Honorable Layn R. Phillips, U.S.D.J. (ret.). I. BACKGROUND For the purposes of the Motion, the Court accepts the factual allegations in the Third-Party

Complaint as true and draws all inferences in the light most favorable to Merck. See Phillips v. Cnty. of Allegheny, 515 F.3d 224, 228 (3d Cir. 2008). The Court also considers any “document integral to or explicitly relied upon in the complaint.” In re Burlington Coat Factory Sec. Litig.,

1 Merck’s Notice of Supplemental Authority pertained to a Report and Recommendation recently entered in a related action venued in the Eastern District of Virginia (see ECF No. 116 (citing FWK Holdings, LLC v. Merck & Co., Civ. A. No. 18-023, 2025 WL 2435909, at *1 (E.D. Va. Aug. 4, 2025), report and recommendation adopted, Civ. A. No. 18-023, 2025 WL 2432609 (E.D. Va. Aug. 22, 2025)).) Cencora’s Notice of Supplemental Authority pertained to an Order recently entered in a related action venued in the District Court of Minnesota. (See ECF No. 144 (citing United HealthCare Servs., Inc. v. Merck & Co., Civ. A. No. 20-1909, 2025 WL 3442799 (D. Minn. Dec. 1, 2025)).) 114 F.3d 1410, 1426 (3d Cir. 1997) (emphasis added) (quoting Shaw v. Digit. Equip. Corp., 82 F.3d 1194, 1220 (1st Cir. 1996)). The factual and procedural backgrounds of this matter are well-known to the parties and were previously recounted in depth by the courts in prior opinions. See, e.g., Humana Inc. v. Merck & Co., Civ. A. No. 23-23023, 2025 WL 2538859 (D.N.J. Sept. 4, 2025); FWK Holdings, LLC v.

Merck & Co., Civ. A. No. 18-023, 2025 WL 2435909 (E.D. Va. Aug. 4, 2025), report and recommendation adopted, Civ. A. No. 18-023, 2025 WL 2432609 (E.D. Va. Aug. 22, 2025); United HealthCare Servs., Inc. v. Merck & Co., Civ. A. No. 20-1909, 2025 WL 3442799 (D. Minn. Dec. 1, 2025). Accordingly, the Court will recount only the factual background and procedural history associated with the Motion. Generally, this action concerns Merck’s alleged monopolization scheme relating to two of its prescription cholesterol-lowering drugs, Zetia and Vytorin. A. The Parties

Merck & Co., Inc. (“Merck & Co.”) is a corporation organized under the laws of New Jersey. (ECF No. 61 ¶ 14.) Merck Sharp & Dohme Corp. is a subsidiary of Merck & Co. organized under the laws of New Jersey and the assignee of patents relevant to this matter. (Id. ¶ 15.) MSP Singapore Co. LLC is also a subsidiary of Merck & Co., Inc. and formerly the exclusive licensee of the relevant patents. (Id. ¶ 21.) Schering-Plough was also a corporation organized under the laws of New Jersey, as was Schering, a wholly owned subsidiary of Schering-Plough and the original assignee of the relevant patents. (Id. ¶¶ 16–17.) Merck & Co. acquired and merged into Schering-Plough in 2009, thereafter changing its name to Merck & Co., Inc., and the company originally known as Merck & Co., Inc. became Merck Sharp & Dohme Corp. (Id. ¶ 18.) AmerisourceBergen Corp. is a corporation organized under the laws of Delaware. (ECF No. 68 ¶ 10.) AmerisourceBergen Drug Corp. (“ABDC”) is a subsidiary of Amerisource Bergen Corp. organized under the laws of Delaware. (Id. ¶ 9.) ABDC is a drug wholesaler, which purchased Zetia, Vytorin, or generic equivalents directly from Merck. (See id. ¶ 27; see also ECF No. 61 ¶ 12.)

Plaintiff Humana Incorporated (“Humana”) is a corporation organized under the laws of Delaware. (ECF No. 61 ¶ 9.) Humana provides healthcare related services, including “insuring risk for prescription drug costs for more than 8 million members in all 50 States, the District of Columbia, and Puerto Rico.” (Id.) When a Humana member fills a prescription for Zetia, Vytorin, or generic equivalents at a pharmacy, Humana pays a large share of the cost; for example, Humana has paid hundreds of millions of dollars to pharmacies for prescriptions for Zetia, Vytorin, and generic equivalents dispensed to Humana members. (Id. ¶ 10.) Humana has also spent millions of dollars on both Zetia and Vytorin dispensed by its own mail-order pharmacy, Humana Pharmacy, Inc. (“HPI”), as well as in retail pharmacy locations. (Id. ¶ 11.) HPI purchases Zetia, Vytorin, and

other drugs relevant to this action from distributors like ABDC. (Id. ¶ 12.) On May 6, 2022, Humana, HPI, and ABDC entered into an agreement assigning ABDC’s rights to assert claims against Merck arising out of or relating to ABDC’s purchases of Zetia and Vytorin, which were later resold to HPI from 2011 to present to Humana. (Id.) It is out of this agreement Humana’s federal antitrust claims arise in the underlying action. (Id. ¶ 13.) B. Multi-District Litigation & Settlement Agreement

On September 22, 2021, Humana filed its initial Complaint against Merck and Glenmark Pharmaceuticals (“Glenmark”) regarding an alleged reverse-payment agreement between the parties to delay the entry of generic competition to Zetia (ECF No. 1), which was subsequently transferred to the Eastern District of Virginia and consolidated in an ongoing multi-district antitrust litigation (the “MDL”), In re Zetia (Ezetimibe) Antitrust Litig., Civ. A. No. 18-2836 (ECF Nos. 5, 6). Both Humana and Cencora were plaintiffs in the MDL and were divided into one of four distinct groups: “Direct Purchaser Plaintiffs,” “Retailer Plaintiffs,” “End Payor Plaintiffs,” and “Insurer Plaintiffs.” (See ECF No. 85-1.) Humana was divided into the “Insurer Plaintiff” group, and

Cencora was divided into the “Direct Purchaser Plaintiff” group. (See ECF No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Global Satellite Communication Co. v. Starmill U.K. Ltd.
378 F.3d 1269 (Eleventh Circuit, 2004)
Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Continental Grain Co. v. Barge FBL-585
364 U.S. 19 (Supreme Court, 1960)
Van Dusen v. Barrack
376 U.S. 612 (Supreme Court, 1964)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Stewart Organization, Inc. v. Ricoh Corp.
487 U.S. 22 (Supreme Court, 1988)
Ferens v. John Deere Co.
494 U.S. 516 (Supreme Court, 1990)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Shaw v. Digital Equipment Corp.
82 F.3d 1194 (First Circuit, 1996)
Mellon Bank, N.A. v. Aetna Business Credit, Inc.
619 F.2d 1001 (Third Circuit, 1980)
Homa v. American Express Co.
558 F.3d 225 (Third Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Humana Inc. v. Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., Schering Corp., and Glenmark Pharmaceuticals Ltd.; Merck & Co., Inc., Merck Sharp & Dohme Corp., Schering-Plough Corp., and Schering Corp. v. AmerisourceBergen Drug Corp., AmerisourceBergen Corp., and Cencora, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/humana-inc-v-merck-co-inc-merck-sharp-dohme-corp-njd-2026.